Clinical Trials
29 trialsNCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT03834272 2026-01-16
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Lumicell, Inc.
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03054298 2025-04-29
CAR T Cells in Mesothelin Expressing Cancers
University of Pennsylvania
Phase 1 Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01997190 2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1 Completed
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03023319 2022-06-14
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
Phase 1 Completed
NCT03071757 2022-04-28
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
Phase 1 Completed
NCT03000257 2022-04-14
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT03652077 2021-11-15
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT03538028 2020-10-30
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed
NCT02585362 2019-01-11
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
Kantonsspital Winterthur KSW
Phase NA Completed
NCT00897442 2016-10-28
Collecting Tumor Samples From Patients With Gynecological Tumors
GOG Foundation
Completed
NCT01521325 2016-09-30
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Morphotek
Phase 1 Completed
NCT00024258 2015-11-25
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00006981 2015-04-30
Immunotoxin Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00066651 2015-04-30
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00325494 2014-07-17
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Morphotek
Phase 1 Completed
NCT00375245 2014-01-17
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Phase 1 Completed
NCT00002515 2013-06-24
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003173 2013-03-07
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00603356 2011-09-27
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Astellas Pharma Inc
Phase 1 Completed